BACKGROUND: Age-related macular degeneration (AMD) is a common cause of visual impairment in individuals >55 years of age worldwide. The varying clinical phenotypes of AMD result from contributions of genetic, epigenetic, and nongenetic (environmental) factors. Genetic studies of AMD have come of age as a direct result of tremendous gains from the human genome project, genome-wide association studies, and identification of numerous susceptibility loci. These findings have implicated immune response, high-density lipoprotein cholesterol metabolism, extracellular matrix, and angiogenesis signaling pathways in disease pathophysiology. MAIN OUTCOME MEASURES: Herein, we address how the wealth of genetic findings in AMD is expected to impact the practice of medicine, providing opportunities for improved risk assessment, molecular diagnosis, preventive, and therapeutic intervention. CONCLUSIONS: We propose that the potential of using genetic variants for monitoring treatment response (pharmacogenetics) may usher in a new era of personalized medicine in the clinical management of AMD. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosures may be found after the references.
BACKGROUND: Age-related macular degeneration (AMD) is a common cause of visual impairment in individuals >55 years of age worldwide. The varying clinical phenotypes of AMD result from contributions of genetic, epigenetic, and nongenetic (environmental) factors. Genetic studies of AMD have come of age as a direct result of tremendous gains from the human genome project, genome-wide association studies, and identification of numerous susceptibility loci. These findings have implicated immune response, high-density lipoprotein cholesterol metabolism, extracellular matrix, and angiogenesis signaling pathways in disease pathophysiology. MAIN OUTCOME MEASURES: Herein, we address how the wealth of genetic findings in AMD is expected to impact the practice of medicine, providing opportunities for improved risk assessment, molecular diagnosis, preventive, and therapeutic intervention. CONCLUSIONS: We propose that the potential of using genetic variants for monitoring treatment response (pharmacogenetics) may usher in a new era of personalized medicine in the clinical management of AMD. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosures may be found after the references.
Authors: Daniel E Weeks; Yvette P Conley; Hui-Ju Tsai; Tammy S Mah; Silke Schmidt; Eric A Postel; Anita Agarwal; Jonathan L Haines; Margaret A Pericak-Vance; Philip J Rosenfeld; T Otis Paul; Andrew W Eller; Lawrence S Morse; J P Dailey; Robert E Ferrell; Michael B Gorin Journal: Am J Hum Genet Date: 2004-05-27 Impact factor: 11.025
Authors: David S Friedman; Benita J O'Colmain; Beatriz Muñoz; Sandra C Tomany; Cathy McCarty; Paulus T V M de Jong; Barbara Nemesure; Paul Mitchell; John Kempen Journal: Arch Ophthalmol Date: 2004-04
Authors: Dennis W Schultz; Michael L Klein; Andrea J Humpert; Christina W Luzier; Vesna Persun; Mitchell Schain; Alison Mahan; Charles Runckel; Maria Cassera; Vasavi Vittal; Trudy M Doyle; Tammy M Martin; Richard G Weleber; Peter J Francis; Ted S Acott Journal: Hum Mol Genet Date: 2003-10-21 Impact factor: 6.150
Authors: Silke Schmidt; Caroline Klaver; Ann Saunders; Eric Postel; Monica De La Paz; Anita Agarwal; Kent Small; Nitin Udar; John Ong; Meenal Chalukya; Anthony Nesburn; Cristina Kenney; Ruth Domurath; Molly Hogan; Tammy Mah; Yvette Conley; Robert Ferrell; Daniel Weeks; Paulus T V M de Jong; Cornelia van Duijn; Jonathan Haines; Margaret Pericak-Vance; Michael Gorin Journal: Ophthalmic Genet Date: 2002-12 Impact factor: 1.803
Authors: C C Klaver; M Kliffen; C M van Duijn; A Hofman; M Cruts; D E Grobbee; C van Broeckhoven; P T de Jong Journal: Am J Hum Genet Date: 1998-07 Impact factor: 11.025
Authors: Stephanie A Hagstrom; Gui-shuang Ying; Gayle J T Pauer; Gwen M Sturgill-Short; Jiayan Huang; Maureen G Maguire; Daniel F Martin Journal: JAMA Ophthalmol Date: 2014-05 Impact factor: 7.389
Authors: Nathan G Lambert; Hanan ElShelmani; Malkit K Singh; Fiona C Mansergh; Michael A Wride; Maximilian Padilla; David Keegan; Ruth E Hogg; Balamurali K Ambati Journal: Prog Retin Eye Res Date: 2016-05-06 Impact factor: 21.198
Authors: Lars G Fritsche; Robert N Fariss; Dwight Stambolian; Gonçalo R Abecasis; Christine A Curcio; Anand Swaroop Journal: Annu Rev Genomics Hum Genet Date: 2014-04-16 Impact factor: 8.929
Authors: Ronald Klein; Stacy M Meuer; Chelsea E Myers; Gabriëlle H S Buitendijk; Elena Rochtchina; Farzana Choudhury; Paulus T V M de Jong; Roberta McKean-Cowdin; Sudha K Iyengar; Xiaoyi Gao; Kristine E Lee; Johannes R Vingerling; Paul Mitchell; Caroline C W Klaver; Jie Jin Wang; Barbara E K Klein Journal: Ophthalmic Epidemiol Date: 2014-02 Impact factor: 1.648